Caixin
Nov 17, 2021 05:11 AM
BUSINESS

BeiGene’s $3.1 Billion Shanghai Share Sale Wins Approval

What’s new: China’s securities regulator Tuesday approved BeiGene’s 20 billion yuan ($3.1 billion) initial public offering (IPO) on the Shanghai Stock Exchange’s Nasdaq-like STAR Market, making it the first Chinese biopharmaceutical company to have shares traded on the Chinese mainland, in Hong Kong and in the U.S.

As the STAR Market’s listing committee cleared BeiGene’s IPO in June, the approval by the China Securities Regulatory Commission was the last step before the share sale.

You've accessed an article available only to subscribers
VIEW OPTIONS
Share this article
Open WeChat and scan the QR code
NEWSLETTERS
Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription
PODCAST
China Stories: The Rural Hardship Behind the Mine Murders That Shocked China
00:00
00:00/00:00